Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus

Antibodies against HDL Components in Ischaemic Stroke and Coronary Artery Disease

(2018) Marta Amaral et al.   THROMBOSIS AND HAEMOSTASIS

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

(2017) Robert S. Rosenson et al.   Nature Reviews Cardiology

Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms

(2017) Panagiotis Antiochos et al.   Frontiers in Immunology

Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes

(2016) Federico Carbone et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus

(2016) Dalia El-Lebedy et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

(2016) Pedro Marques-Vidal et al.   THROMBOSIS AND HAEMOSTASIS

Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study

(2016) Wijtske Annema et al.   Scientific Reports

Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction

(2015) Maria Rubini Gimenez et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?

(2015) Sabrina Pagano et al.   PLoS One

Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4

(2015) Vincent Braunersreuther et al.   THROMBOSIS AND HAEMOSTASIS

Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study

(2015) Danish Saleheen et al.   Lancet Diabetes & Endocrinology

Alterations in plasma lecithin:cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: Implications for cardiac outcome

(2014) Robin P.F. Dullaart et al.   ATHEROSCLEROSIS

Molecular Mechanisms of Cellular Cholesterol Efflux

(2014) Michael C. Phillips   JOURNAL OF BIOLOGICAL CHEMISTRY

Definition of Human Apolipoprotein A-I Epitopes Recognized by Autoantibodies Present in Patients with Cardiovascular Diseases

(2014) Priscila Camillo Teixeira et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

(2014) Anand Rohatgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Serum Cholesterol Esterification Rates Predict Coronary Heart Disease and Sudden Death in a General Population

(2013) Shin-ichiro Tanaka et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research

(2013) Michela Triolo et al.   Biomarkers in Medicine

Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes

(2013) Michela Triolo et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Cardioprotective functions of HDLs

(2013) Kerry-Anne Rye et al.   JOURNAL OF LIPID RESEARCH

Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex

(2012) S. Pagano et al.   JOURNAL OF INTERNAL MEDICINE

High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: A nested case–control study

(2011) Paul J.W.H. Kappelle et al.   ATHEROSCLEROSIS

Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability

(2011) Fabrizio Montecucco et al.   EUROPEAN HEART JOURNAL

Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis

(2010) Nicolas Vuilleumier et al.   ARTHRITIS AND RHEUMATISM

Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice

(2010) Roshni Srivastava et al.   ARTHRITIS AND RHEUMATISM

Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction

(2010) N. Vuilleumier et al.   EUROPEAN HEART JOURNAL

High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome

(2010) PRJ Ames et al.   LUPUS

High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: Possible attenuation of cardioprotection associated with high HDL cholesterol

(2009) Robin P.F. Dullaart et al.   ATHEROSCLEROSIS

HDL as a Biomarker, Potential Therapeutic Target, and Therapy: FIG. 1.

(2009) Mohamad Navab et al.   DIABETES

The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the −629C→A cholesteryl ester transfer protein promoter polymorphism: Role of lecithin:cholesterol acyltransferase activity

(2008) S BORGGREVE   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome

(2008) Nicolas Vuilleumier et al.   CLINICAL SCIENCE

Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol

(2008) Robin P F Dullaart et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus

(2008) J. R. Batuca et al.   RHEUMATOLOGY

Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: Roles of pre β-HDL, phospholipid transfer protein and cholesterol esterification

(2007) R. de Vries et al.   ATHEROSCLEROSIS